# The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers

> **NCT06246019** · — · UNKNOWN · sponsor: **Hospital del Mar Research Institute (IMIM)** · enrollment: 200 (estimated)

## Conditions studied

- Alzheimer Disease
- Cognitive Impairment
- Dementia
- Neurodegenerative Diseases
- Frontotemporal Dementia
- Lewy Body Disease
- Vascular Dementia

## Interventions

- **DIAGNOSTIC_TEST:** Early adoption of blood-based biomarkers for Alzheimer's disease

## Key facts

- **NCT ID:** NCT06246019
- **Lead sponsor:** Hospital del Mar Research Institute (IMIM)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-07
- **Primary completion:** 2025-05
- **Final completion:** 2025-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246019, "The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06246019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*